Research type:
|
HTA Technology Assessment Report |
Title (lead author) etc:
|
Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation (Waugh) 247 pages, Volume 14, number 36 |
DOI
|
10.3310/hta14360 |
View/print executive summary
View/print abstract
View full text in pdf format (1881 KB)
Go to our correspondence page to comment on this publication
|
Headline: |
Although economic analyses are subject to considerable uncertainty, the study supports recent NICE clinical guidelines that NPH should be the preferred first line choice of insulin in type 2 diabetes. This finding is driven by much the higher costs and limited clinical advantage of the comparators long acting insulin analogues glargine and detemir. Exenatide appeared clinically and cost effective as an alternative to starting insulin immediately on failure of oral therapy for glucose lowering. Sitagliptin and vildagliptin had similar clinical effectiveness as glitazone but this was achieved at lower cost and side effects |
This report should be referenced as follows: |
Waugh N, Cummins E, Royle P, Clar C, Marien M, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess
2010;14(36).
|
Project ref: |
08/05/01 |
Original project title: |
Newer agents for blood glucose control in type 2 diabetes |
Chief Investigator: |
Aberdeen HTA Group, University of Aberdeen
|
Start Date: |
May 2008 |
Date of publication in HTA journal series |
August 2010
|
Cost: |
This project was commissioned by the HTA programme on a call-off contract basis. |
Project Protocol: |
Project protocol (pdf format, 73 kbytes)
|
Printed copies of this title despatched:
|
91 (Figures relate to the previous calendar month) |
URL of this page: |
http://www.hta.ac.uk/1743 |
News feeds